A Medical Science Liaison costs a pharma company between 280,000 and 380,000 dollars per year fully loaded. They are among the most expensive humans in the entire commercial organization, second only to senior medical affairs leadership.
What they actually spend their time on is one of the great unmeasured tragedies in pharma operations.
The 70-30 Breakdown
Time-and-motion studies across MSL teams in 2024 and 2025 produced a remarkably consistent finding. The average MSL spends 70 percent of their working hours on administrative tasks. Calendar coordination. CRM data entry. Internal email. Report writing. Travel logistics. Compliance documentation. Slide deck production for the sixth internal review of a strategy that was decided two months ago.
Of the 30 percent that goes to actual scientific work, roughly half is rework. The same literature review done for the third time because the previous one was filed somewhere no one can find. The same KOL profile rebuilt because three different team members own different versions. The same insight document polished for an internal stakeholder who already heard the insight verbally last week.
Net result: MSLs spend roughly 15 percent of their week on novel, durable scientific work. The other 85 percent is admin, rework, or low-value coordination.
Why This Happens
The honest reason is structural, not personal. Medical affairs operations were designed for an era of 50 MSLs serving 200 KOLs. The same processes have been scaled to 500 MSLs serving 5,000 KOLs without redesigning them. Most of the inefficiency is structural slack that nobody removed because nobody was responsible for removing it.
The compounding factor is that MSL output is hard to measure. Sales reps have script lifts. Marketing has engagement metrics. Medical affairs has insights, KOL relationships, and educational impact. None of these are easily quantified. When output is hard to measure, input becomes the proxy. So MSLs are measured on activity volume, not value created.
This produces a vicious incentive. Every MSL learns that adding another internal report or another CRM entry is rewarded. Spending two hours reading a NEJM paper and not documenting it is invisible. So the work that matters gets squeezed out by the work that gets noticed.
The Cost
If 85 percent of MSL time is admin or rework, and an MSL costs 330,000 dollars per year, the company is paying 280,000 dollars per MSL per year for activity that produces no durable value.
Multiply across a 100-MSL team and you get 28 million dollars per year in compensation flowing to non-productive activity. That number should be larger than the entire technology investment most medical affairs functions are willing to approve.
What Actually Fixes This
The fix is not "more efficient meetings" or "better CRM training." The fix is structural.
First, eliminate or automate the admin layer. Calendar coordination, CRM logging, internal report generation, slide production. All of these can be done by AI agents with human approval. The MSL stops doing them. The agent does. The MSL approves and the agent files. This alone recovers 30 to 40 percent of an MSL's week.
Second, build durable knowledge infrastructure. The reason rework exists is that no one can find what was done before. A proper internal knowledge base, with searchable insights, KOL profiles, literature reviews, all linked, eliminates 80 percent of rework.
Third, redefine what is measured. Move from activity to outcomes. Track new insights surfaced, KOL relationships deepened, educational programs delivered, scientific questions answered. Stop counting CRM entries.
The technology to do all three exists today. The barrier is structural, not technical. Medical affairs leadership has to want this enough to redesign the operating model, and most do not.
The Implication
The MSL function is one of the highest-leverage operational opportunities in pharma. A 30 percent productivity recovery on a 100-MSL team is worth 10 million dollars per year. A 50 percent recovery is worth 16 million.
The companies that capture this advantage will have medical affairs functions that do twice the science with the same headcount. The companies that do not will keep paying senior salaries for junior outputs.
The math is clear. The will is rare.
That gap is the entire opportunity.
